Haw Par Corporation Limited (SGX: H02)
Health Care · Pharmaceuticals · SG
S$12.77
+0.55% today · -13.6% 1Y
Haw Par Corporation Limited (SGX: H02) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $2.21B and employs 595 people.
Over the last twelve months the share price has lost 13.6%, trading between 12.94 and 18.27.
Tweenvest scores Haw Par Corporation Limited across four factors: quality 71/100, value 61/100, growth 71/100, dividend 50/100. Its strongest factor is quality.
H02 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $2.21B
- Revenue (TTM)
- $169.66M
- P/E
- 12.34
- EPS
- 1.04
- Dividend yield
- 3.15%
- Beta (5Y)
- 0.16
- 52-week high
- S$18.27
- 52-week low
- S$12.94
- Avg volume (3M)
- —
- Shares outstanding
- 221.37M
- Employees
- 595
- Next earnings
- —
About Haw Par Corporation Limited
Established in Singapore in 1969, Haw Par Corporation Limited specializes in the manufacturing, marketing, and global trade of healthcare products, serving markets in Singapore, ASEAN countries, other Asian regions, and beyond. The company's business activities are structured into three main segments: Healthcare, Investments, and Others. Its Healthcare segment primarily produces and distributes topical pain relief solutions, prominently featuring the Tiger Balm and Kwan Loong brands. The Investments segment focuses on acquiring publicly traded securities. Additionally, Haw Par owns and leases out a diverse portfolio of investment properties, comprising 45,324 square meters of commercial and industrial real estate across Singapore and Malaysia. The corporation also offers family and tourist-oriented leisure experiences, notably through oceanariums. Furthermore, it provides leasing services for land, buildings, and office spaces, in addition to offering management support.
- ISIN
- SG1D25001158
- Founded
- 1969
- Listed since
- Jan 3, 2000
- Exchange
- Singapore Exchange
- Currency
- SGD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Shandong Buchang Pharmaceuticals Co., Ltd.SHSE: 603858 | $2.29B | CN¥14.81 | +1.16% |
| Prestige Consumer Healthcare Inc.NYSE: PBH | $2.28B | $48.23 | +0.75% |
| Bausch Health Companies Inc.NYSE: BHC | $2.26B | $6.04 | 0.00% |
| ApicHope Pharmaceutical Group Co., Ltd.SZSE: 300723 | $2.24B | CN¥33.42 | +0.45% |
| Pharvaris N.V.NasdaqGS: PHVS | $2.18B | $31.10 | -0.29% |
| BrightGene Bio-Medical Technology Co., Ltd.SHSE: 688166 | $2.18B | CN¥33.53 | -6.37% |
| Tonghua Golden-Horse Pharmaceutical Industry Co,LtdSZSE: 000766 | $2.16B | CN¥14.97 | -1.25% |
| China Resources Jiangzhong Pharmaceutical Co.,LtdSHSE: 600750 | $2.15B | CN¥22.88 | +1.24% |
Figures last refreshed Oct 11, 2026.